期刊论文

中文

中医学

2166-6067

2019

08

1

61-67

10.12677/TCM.2019.81013

本校为第一机构

Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world; the prevalence of NAFLD in different populations is 25% - 45%; due to the global increase in obesity and diabetes prevalence, NAFLD is on the rise. NAFLD ranges from clinically benign hepatic steatosis to non-alcoholic fatty liver disease (NASH), an intermediate disease, to cirrhosis and even liver failure and death. Considering the high prevalence of NAFLD and its adverse impact on patients’ quality of life, curcumin is Curcuma longa L.,...

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world;the prevalence of NAFLD in different populations is 25% - 45%;due to the global increase in obesity and diabetes prevalence, NAFLD is on the rise. NAFLD ranges from clinically benign hepatic steatosis to non-alcoholic fatty liver disease (NASH), an intermediate disease, to cirrhosis and even liver failure and death. Considering the high prevalence of NAFLD and its adverse impact on patients’ quality of life, curcumin is Curcuma longa L., a bioactive...